Sage Therapeutics Inc (NASDAQ: SAGE) kicked off on Friday, down -5.13% from the previous trading day, before settling in for the closing price of $5.85. Over the past 52 weeks, SAGE has traded in a range of $4.62-$28.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 4267.58%. While this was happening, its average annual earnings per share was recorded 28.60%. With a float of $53.88 million, this company’s outstanding shares have now reached $61.17 million.
Let’s determine the extent of company efficiency that accounts for 487 employees. In terms of profitability, gross margin is 91.75%, operating margin of -349.3%, and the pretax margin is -317.29%.
Sage Therapeutics Inc (SAGE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sage Therapeutics Inc is 11.92%, while institutional ownership is 85.30%. The most recent insider transaction that took place on Dec 10 ’24, was worth 41,441.
Sage Therapeutics Inc (SAGE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.60% per share during the next fiscal year.
Sage Therapeutics Inc (NASDAQ: SAGE) Trading Performance Indicators
Take a look at Sage Therapeutics Inc’s (SAGE) current performance indicators. Last quarter, stock had a quick ratio of 10.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.58, a number that is poised to hit -1.49 in the next quarter and is forecasted to reach -3.72 in one year’s time.
Technical Analysis of Sage Therapeutics Inc (SAGE)
Looking closely at Sage Therapeutics Inc (NASDAQ: SAGE), its last 5-days average volume was 1.16 million, which is a drop from its year-to-date volume of 1.39 million. As of the previous 9 days, the stock’s Stochastic %D was 39.23%. Additionally, its Average True Range was 0.41.
During the past 100 days, Sage Therapeutics Inc’s (SAGE) raw stochastic average was set at 22.46%, which indicates a significant decrease from 37.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.92% in the past 14 days, which was lower than the 74.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.67, while its 200-day Moving Average is $9.38. However, in the short run, Sage Therapeutics Inc’s stock first resistance to watch stands at $5.68. Second resistance stands at $5.82. The third major resistance level sits at $5.94. If the price goes on to break the first support level at $5.43, it is likely to go to the next support level at $5.31. Now, if the price goes above the second support level, the third support stands at $5.18.
Sage Therapeutics Inc (NASDAQ: SAGE) Key Stats
The company with the Market Capitalisation of 339.51 million has total of 61,173K Shares Outstanding. Its annual sales at the moment are 86,460 K in contrast with the sum of -541,490 K annual income. Company’s last quarter sales were recorded 11,870 K and last quarter income was -93,550 K.
